Verge Genomics, an AI-based neurological therapeutic developer, has raised USD 98 million in an oversubscribed Series B funding round led by BlackRock with participation from Eli Lilly and Company, Merck Global Health Innovation Fund, Section 32, and Vulcan Capital, along with several existing investors. This brings the company’s total funds raised to USD 134 million.
The funds will be used to scale up its preclinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. The company also intends to further develop its proprietary technology to expand the drug discovery process, including translational medicine and clinical development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.